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T cells in atopic dermatitisTo the Editor:
Atopic dermatitis (AD) is a chronic and relapsing skin disease
characterized by inflammation and pruritus. In our previous
hospital-based study of 1008 patients with AD, we found that
the proportion of patients with severe ADwas 10.7%.1 Moreover,
AD is a huge economic burden for families and society in general
due to the long course of relapsed disease.
Regulatory T (Treg) cells control immune homeostasis and
balance immune responses during inflammation. Treg cells
suppress immune responses by interacting with effector T cells
or antigen-presenting cells.2 Recent clinical research has found
that parents, particularly mothers, who have a history of atopy
could have babies with less stable FOXP31 Treg cells in cord
blood. These babies have the onset of AD less than 1 year after
birth.3 Therefore, it is likely that the abnormal numbers of Treg
cells weaken the inhibition of TH2 lymphocytes, thus resulting
in AD inflammation.
Lidocaine is a widely used short-acting local anesthetic and
antiarrhythmic agent. Previous studies demonstrated that lido-
caine attenuated bronchoconstriction in patients with severe
asthma, which enabled the dosage of oral corticosteroids to be
reduced or eliminated in long-term treatment.4 Because of the
similarity of allergic diseases, lidocaine was used as a treatment
for AD in China. Previous studies have shown that lidocaine
dose-dependently inhibits the proliferative response and release
of inflammatory factors from Staphylococcal enterotoxins A-
and Staphylococcal enterotoxins B–stimulated PBMCs in pa-
tients with AD, contributing to clinical remission.5
In vivo, we sought to explore the effect of lidocaine on Treg
cells and other key cytokines in patients with AD and murine
AD models. Twenty patients were administered lidocaine
(3 mg/kg per day) via a slow intravenous drip for 14 days. Duringwithin the third year of life (P values from Mann-
FIG 1. Effects of lidocaine therapy on lesion severity and Treg cells in patients with AD. A, Photographs of 4
patients with AD before and after lidocaine therapy (14 days). B, The SCORAD index of patients with AD
declined significantly after lidocaine treatment (n 5 20). C and D, FOXP3 mRNA expression in PBMCs
(via RT-PCR) and the proportion of Treg cells in PBMCs (via flow cytometric analysis) were upregulated
in patients with AD after lidocaine treatment compared with before treatment (n 5 20). E, FOXP3 protein
expression in whole lesioned skin from patients with AD after lidocaine treatment was significantly
increased compared with before treatment (n 5 4) (via Western blot analysis). F and G, FOXP31 cell
numbers in the lesioned skin increased in patients with AD after lidocaine therapy compared with
before treatment (n 5 3) (via immunochemistry analysis). Original magnification: a and c, 3100; b and d,
3200. *P < .05, **P < .01, and ***P < .001. Bars indicate mean 6 SEM of 3 independent experiments.
Statistical analyses were performed with paired t test. HC, Healthy control; SCORAD, SCORing Atopic
Dermatitis.
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FIG 2. Effects of lidocaine onmurine Treg-cell differentiation and its specific signaling pathway.A-C, In vitro
Treg-cell differentiation: Lidocaine could upregulate the proportion of Treg cells (via flow cytometry), FoxP3
protein expression level, and P-Smad3/Smad3 level (via Western blot) at a concentration of 0.8 mmol/L.
D, SIS3 (5 mM) significantly blocked the promotion of lidocaine to Treg-cell differentiation at a concentration
of 0.8 mmol/L (via Western blot). *P < .05, **P < .01, and ***P < .001. Bars indicate mean 6 SEM of 3
independent experiments. Statistical analyses were performed with the paired t test.
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patients. The clinical manifestations of AD markedly improved
(Fig 1,A), and the SCORingAtopic Dermatitis index significantly
declined (Fig 1, B). We found that FOXP3mRNA expression and
the proportion of Treg cells in PBMCs from patients with ADwere significantly decreased compared with that in healthy indi-
viduals. In addition, FOXP3mRNA expression level and the pro-
portion of Treg cells in patients with AD after lidocaine treatment
significantly increased compared with before treatment (Fig 1, C
and D). Four patients permitted skin biopsies and their skin
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sion levels. Consistent with FOXP3 mRNA expression levels in
PBMCs, the expression of FOXP3 mRNA and protein levels in
lesioned skin was also upregulated (see Fig E1, B, in this article’s
Online Repository at www.jacionline.org; Fig 1, E). Immuno-
chemistry analysis showed that FOXP31 cell numbers in the
skin increased in the 3 patients with AD after lidocaine therapy
(Fig 1, F andG). Furthermore, we established ADmurine models
with topical ovalbumin (OVA) as previously described,6 of which
each group included 5 mice. Then, we treated OVA-sensitized
mice (via tail vein injection) with different doses of lidocaine:
1.5 mg/kg per day (OVA Lido1.5) and 3.0 mg/kg per day (OVA
Lido3.0) for 7 days. A recent report has shown that cyclosporine
elevates the proportion and absolute number of Treg cells in pa-
tients with AD; however, the function was not significantly
different from that in healthy controls.7 Therefore, cyclosporine
(2.5 mg/kg per day) was intragastrically administered for
7 days as a positive control (OVA Cys). The phenotypes of
mice treated with lidocaine and cyclosporine improved compared
with mice treated with saline (see Fig E2, A, in this article’s On-
line Repository at www.jacionline.org). In addition, the index of
lesion severity and histopathological findings were consistent
with the improved phenotypes (Fig E2, B and C). We subse-
quently measured FoxP3mRNA and protein expression in whole
lesioned skin using RT-PCR and Western blot. We also used flow
cytometric analysis to determine the proportion of Treg cells in
the dermis of lesioned skin, spleen, and lymph nodes in the 4 treat-
ment groups. Compared with the OVA saline group, the propor-
tion of Treg cells of murine lesions and FoxP3 mRNA and
protein expression levels in the lidocaine treatment groups and
the cyclosporine treatment group were significantly upregulated
(see Fig E3, A-C, in this article’s Online Repository at www.
jacionline.org). However, no significant difference was detected
in the proportion of Treg cells in murine spleen and lymph nodes
from the OVALido1.5 andOVALido3.0 treatment groups and the
OVA Cys treatment group (Fig E3, E). Furthermore, lidocaine
therapy ameliorated the TH1/TH2 cell and IL-17A/IL-17E cyto-
kine imbalance in patients with AD andmurine ADmodels. In pa-
tients with AD, IFN-g, IL4, and IL17A mRNA expression levels
were significantly upregulated in PBMCs after lidocaine treat-
ment in contrast to those before treatment while IL17E mRNA
level was downregulated significantly (Fig E1, A). Furthermore,
IL17EmRNA level of whole lesioned skin decreased significantly
in patients with AD after lidocaine treatment (Fig E1, B). IL-17E
is involved in the TH2-dominant immune response and its down-
regulation might contribute to the amelioration of symptoms.
Moreover, the relationship between IFN-g and IL-4 as well as
that between IL-17A and IL-17E is interacting. Consequently,
we presumed that IL-4 mRNA expression was upregulated to
inhibit the elevation in IFN-g mRNA expression while IL-17A
mRNA expression increased in response to the decrease in IL-
17E mRNA expression level. Although lidocaine therapy did
not totally block the upregulation of cytokines mentioned above,
it still disrupted the amplification cycle of skin inflammation and
ameliorated symptoms. Owning to the less complicated neuro-
endocrine-immune networks and habitation in pathogen-free
environment, the regulation of inflammatory factors in murine
models was more explicit. Compared with the OVA saline group,
the expression of IFN-g mRNA in the OVA Lido3.0 group was
significantly upregulated, whereas IL-4 and IL-17E mRNA levelsin the OVA Lido1.5, OVA Lido3.0, and OVA Cys groups were
significantly downregulated (Fig E3, D).
In vitro, the splenocytes of FoxP3-EGFP mice were purified to
prepare CD41CD252 cells as naive CD41 T cells. Cells were
stimulated with antibodies against CD3 (10 mg/mL), CD28
(2 mg/mL), TGF-b (5 ng/mL), and IL-2 (40 ng/mL). The cells
were collected for flow cytometry and Western blot analysis
4 days later. First, we used CCK8 analyses to identify safe levels
of lidocaine and determined that 0.8 mMwas appropriate (see Fig
E4, A, in this article’s Online Repository at www.jacionline.org).
At this concentration, lidocaine upregulated the proportion of
Treg cells and FoxP3 protein expression level (Fig 2, A and B).
Western blot analyses were used to elucidate potential
target signaling pathways. We found that 0.8 mM lidocaine
significantly promoted Treg-cell differentiation, activating the
Smad3/TGF-b signaling pathway (Fig 2, C), but not through
the Smad2/TGF-b or nuclear factor kappa B signaling pathways
(Fig 2, C; Fig E4, B). SIS3 (5 mM), an inhibitor of Smad3, was
used to define the authenticity of lidocaine-induced regulation
of Treg cells. We found that SIS3 significantly downregulated
the proportion of Treg cells in the presence of 0.8 mM lidocaine,
which established categorically that Treg cells regulated by
lidocaine were at least in part, if not wholly, dependent on
Smad3 activity (Fig 2, D).
To our knowledge, the present study is the first report to
demonstrate that lidocaine therapy can ameliorate the severity of
lesioned skin in patients with AD and murine AD models. Our
study has also uncovered the critical role and molecular
mechanism of lidocaine in Treg-cell regulation. In addition, we
found that lidocaine promoted FoxP3 transcription by activating
TGF-b–induced Smad3 phosphorylation. Lidocaine therapy
also ameliorated the TH1/TH2 cell and IL-17A/IL-17E
cytokine imbalance in patients with AD and murine AD models.
These novel findings indicate that lidocaine might exert
regulatory effects on immune cells and thus reduce AD
inflammation.
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http://dx.doi.org/10.1016/j.jaci.2015.07.039Decreased IgM, IgA, and IgG
response to pneumococcal vaccine
in children with transient hypo-
gammaglobulinemia of infancyFIG 1. Median IgM (A), IgA (B), and IgG (C) anti-PCP antibodies in HC (white
bars) and children with UH (black bars) before (pre) and 4 weeks after each
PV dose (post-I, post-II, and post-III). *P values <.05. The continuous line
compares pre- and postvaccination titers within the same cohort. The
dotted line compares postvaccination titers between HC and children
with UH.To the Editor:
Transient hypogammaglobulinemia of infancy (THI) is a
primary antibody deficiency occurring in the first years of life
and is characterized by a delay in the immunoglobulin production
that spontaneously recovers in early infancy. In the young
symptomatic child with low IgG levels and more than 2% B
cells, there are no peculiar clinical and immunologic features that
allow discrimination between self-limiting THI, common vari-
able immunodeficiency, or other dysgammaglobulinemias. Only
those patients whose IgG levels have normalized after age 4 years
have a definitive THI diagnosis made a posteriori.1,2
In a previous study, we demonstrated that a subgroup of
children with putative THI shares abnormalities of B-cell
memory subsets with other defined immune deficiencies, and
cautiously suggested the term ‘‘hypogammaglobulinemia during
infancy’’ to define conditions in which it is not yet possible to
discriminate THI from other primary antibody defects.3 Recently,
according to the new European Society for Immunodeficiencies
diagnostic criteria, a working definition of ‘‘unclassified hypo-
gammaglobulinemia’’ (UH) has been introduced to register pa-
tients with IgG values below age-related normal values detected
in the first 3 years of life that will be moved to THI diagnosis if
there is spontaneous resolution before age 4 years (http://esid.
org/Working-Parties/Registry/Diagnosis-criteria).
Measurement of pneumococcal antibodies is an important tool
in the immunologic assessment of patients with suspected
immune deficiencies.4
The aim of this study was to analyze prospectively IgM-, IgA-,
and IgG-antibody responses to pneumococcus vaccine (PV) in
children with UH until THI or other immune deficiencies criteria
were met.In the context of the Italian Primary Immunodeficiency
Network, we enrolled 21 patients (age range, 12-36 months)
with a history of recurrent infections who had an initial diagnosis
of UH in accordance with our national protocol for THI (http://
www.aieop.org/stdoc/prot/rec_thi_en_06.pdf) and monitored
them until age 4 years with regular clinical and immunologic
evaluations. Eighteen healthy age-matched children (HC) (age
range, 15-40 months) were used as controls. Informed consent
was obtained from the patient’s parents. The Institutional Ethical
Committee approved the study. All patients and HC received 3
doses of 7-valent conjugated pneumococcus vaccine (PCV 7, Pre-
vnar, Pfizer), with the exception of 5 children with UH and 6 HC
who received the third PV dosewith unconjugated pneumococcus
polyvalent vaccine (Pneumo23; Aventis, Milan, Italy) because
they were older than 2 years. Serum samples were collected
from children with UH and HC before and 4 weeks after each
METHODS
Subjects
Patients. Before the study, patient consent and ethical approval were
obtained. Subjects included in this study were 20 patients with AD with
lidocaine therapy and 20 healthy age- and sex-matched volunteers. Patients with
AD younger than 65 years were severely affected and fulfilled the criteria of
Hanifin and Rajka. The clinical severity during therapy was monitored by
using the SCORing Atopic Dermatitis index (0-24, mild AD; 25-50, moderate
AD; 51-103, severe AD). None of the patients had other skin diseases
besides AD, and they did not receive any systemic corticosteroids in the recent
3 months.
Mice. Balb/C mice (6- to 8-week-old female mice) were purchased from
Slack Laboratory (Shanghai, China). The mice were anesthetized and their
backs were shaved. Skin injury was induced by repeated tape-stripping, after
which 100 mg of OVA in 100 mL of saline, or saline only, was applied on a
specific patch and attached to the injured area. Treatment was repeated with
the 1-week sensitization period after which a 2-week resting period was kept
before the second and similar sensitization week. The lesional severity was
assessed every week. The standards used are shown as follows: 0 point for
none, 1 point for mild, 2 points for moderate, and 3 points for severe lesioned
skin. The symptoms included erythema, papule/edema, excoriation, oozing,
lichenification, and dry skins. At the end of the seventh week, the mice in the
saline group and the OVA group were sacrificed and samples were collected
24 hours after the last treatment. The other 4 groups were treated with saline,
lidocaine 1.5 mg/kg per day and lidocaine 3.0 mg/kg per day with tail
vein injection, and cyclosporin 2.5 mg/kg per day by intragastric
administration for 7 days, which were accompanied by sustained OVA
sensitization (each group n5 5). Mice in the above 4 groups were sacrificed at
the eighth week.
FoxP3-EGFPmicewere offered by the research group of Professor Honglin
Wang in the Institute of Medical Sciences, Shanghai Jiao Tong University
School of Medicine.
Naive CD41 T cells were prepared with FoxP3-EGFP mice.
Cells. PBMCs were isolated from heparinized venous blood from patients
with ADwith Ficoll-Paque plus (Pharmacia, Uppsala, Sweden) within 6 hours
after bleeding by means of density gradient centrifugation and cells were
resuspended in RPMI 1640 medium supplemented with 5% pooled type AB
normal human serum (Sigma-Aldrich, St Louis, Mo) for further total RNA
extraction and flow cytometry.
Murine CD41 T cells were purified from murine splenocytes by negative
selection, which used an MACS system with biotin-antibody cocktail and
antibiotin microbeads. Negatively selected CD41 cells were further positively
selected into CD41CD252 cells as naive CD41 T cells by using CD252 PE
antibody and anti-PE MicroBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany).
Single-cell suspensions from the murine inflamed skins were prepared by
cutting the skin samples into small pieces, then passing them through a 70-mm
cell strainer, washing with PBS, and filtrating with a 40-mm cell strainer again
(Becton-Dickinson & Company, Franklin Lakes, NJ).
For the preparation of dermal single-cell suspension, lesioned skins
were cut into 3 mm 3 3 mm sections and immersed in DispaseII at 48C
overnight. The sections were then washed thrice by Hank’s fluid without Ca21
and Mg21. The dermis was gently isolated with ophthalmic forceps and
vibrated with collagenase at 378C for 20 minutes and with DNAase for the
next 25 minutes. (All the products mentioned above were from
Sigma-Aldrich.)
Analysis of lidocaine cytotoxicity on PBMCs
CD41 T cells (1 3 105 for cells/well) were seeded onto a 96-well plate in
medium with FBS. Lidocaine of different concentrations was added into the
plate (0, 0.1, 0.2, 0.4, 0.8, 1.2, 1.6, and 2.0 mM). Water-soluble tetrazolium
salts were added to each well (CCK-8, Dojindo, Mashiki-machi,
Kamimashiki-gun, Kumamoto, Japan). Cells were incubated for 4 hours at
378C. Microplate reader was used to detect absorbance, which was measured
at 450 nm with a reference filter at 650 nm.
In vitro Treg-cell differentiation
Naive CD41 T Cells were cultured in complete medium. Purified
CD41CD252 cells were stimulated with antibodies against CD3
(10 mg/mL) and CD28 (2 mg/mL) (Becton-Dickinson & Company) and
TGF-b (5 ng/mL) and IL-2 (40 ng/mL) (R&D Systems, Minneapolis,
Minn). SIS3 (5 mM) was added to the culture at 18 hours after iTreg-cell dif-
ferentiation to define the specificity of lidocaine-mediated Smad3 induction.
Flow cytometry
Anti-mouse CD4APC and anti-mouse CD25 PerCP-Cyanine5.5 were used
for surface staining. Intracellular staining for FoxP3 and Helios was donewith
anti-mouse/rat FoxP3 PE and anti-Helios FITC according to the manufac-
turer’s instruction (eBioscience, San Diego, Calif).
Isolated 1 3 106/mL PBMCs were stained with human Treg-cell staining
kit. Briefly, cells were suspended in a staining buffer and incubated with a
surface marker (CD4, CD25, CD127) for 30 minutes at 48C in the dark. After
6 minutes of washing with the staining buffer at 300 g, cells were incubated
overnight with fixation/permeabilization buffer at 48C in the dark.
Subsequently, the cells were stained with PE anti-human FOXP3 for 30 mi-
nutes at room temperature in the dark and washed twice (eBioscience).
RNA isolation and analysis
TotalRNAwas extracted fromPBMCs andmurine skinswithTRIzolReagent
(Invitrogen, Carlsbad, Calif) according to the manufacturer’s instructions. It was
used as a template for cDNA synthesis by using SuperScript III reverse
transcriptase (Invitrogen). Real-time quantitative PCR analysis was performed
with 7500 Fast Real Time PCR system (Applied Biosystems, Foster City, Calif)
using primers and probes. b-Actin was used as an endogenous control. All
primers and probes were purchased from Sangon Biotech (Shanghai, China).
Western blot analysis
Western blot analysis was performed with anti-FoxP3 (eBioscience),
Smad3, Phospho-Smad3, Smad2, Phospho-Smad2, nuclear factor kappa b
p65, Phospho-nuclear factor kappa b p65, IkBa, Phospho-IkBa rabbit mAb,
and anti–b-actin mouse mAbs (Cell Signaling Technology, Beverly, Mass)
followed by horseradish peroxidase–conjugated goat anti-rabbit IgG and goat
anti-mouse IgG (H1L) (Beyotime Biological Technology, Jiangsu, China)
and ECL detection (Thermo Fisher Scientific, Inc, Waltham, Mass).
Histology
Skins were fixed in 10% formalin and embedded in paraffin. Multiple
4-mm-thick sections were stained with hematoxylin-eosin.
Immunochemistry
Samples obtained from exposed skin were immersed in 4% formamint-
fixed, and paraffin-embedded blocks were archived. Sections (4 mm) were
used for immunoperoxidase staining to detect FOXP3 (eBiosciences).
Horseradish peroxidase-conjugated secondary antibody anti-rat IgG (H1L)
was purchased from Sangon Biotech.
Statistical analyses
Datawere analyzed by using theGraphPad Prism 5 package (GraphPad Inc,
La Jolla, Calif). Two-tailed student t tests and nonparametric Mann-Whitney
test were used to compare values. P values are designated as P < .05 (*),
P < .01 (**), and P < .001 (***).
Study approval
All participants or their legal guardians provided informed consent. All
procedures, forms, and protocols were approved by the Ethics Committee of
Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of
Medicine. The Animal Care and Use Committee of Xinhua Hospital approved
all animal experiments.
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FIG E1. Lidocaine regulated other cytokines in PBMCs and lesioned skins of patients with AD. A, IFN-g, IL-4,
and IL-17A mRNA expression levels were significantly upregulated in PBMCs of patients with AD after
lidocaine treatment in contrast to those before treatment, whereas IL-17E mRNA level was downregulated
significantly (n 5 20). B, FOXP3mRNA level significantly increased, whereas IL-17E mRNA level decreased
in whole lesioned skins of patients with AD after lidocaine treatment in contrast to those before treatment
(n5 4). *P < .05 and **P < .01. Bars indicatemean6 SEM of 3 independent experiments. Statistical analyses
were performed with nonparametric Mann-Whitney test. HC, Healthy control.
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FIG E2. Effects of lidocaine therapy on lesional severity in OVA-sensitized murine models. A, Lidocaine
significantly improved the phenotypes in mice of lidocaine (OVA Lido1.5 and OVA Lido3.0) and cyclosporin
(OVA Cys) treatment groups compared with the OVA saline group (n 5 5). B, Lidocaine significantly
improved the histopathologic findings with significant decline in the number of infiltrating cells in mice
of lidocaine (OVA Lido1.5 and OVA Lido3.0) and cyclosporin (OVA Cys) treatment groups compared with
the OVA saline group (n 5 5). Original magnification: 350. C, Except the OVA saline group, the murine
scores of severity in the other 3 groups (OVA Lido1.5, OVA Lido3.0, ad OVA Cys) after treatment were
significantly decreased in contrast to those before treatment (n 5 5). Bars indicate mean 6 SEM (n 5 5)
of 2 independent experiments. Statistical analyses were performed with the paired t test. ***P < .001.
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FIG E3. Effects of lidocaine therapy on OVA-sensitized murine models. A-C, Compared with those of the
OVA saline group, the proportion of Treg cells (via flow cytometry) in murine dermis of lesioned skin and
FoxP3 mRNA (via RT-PCR) and protein expression level (via Western blot) of whole lesioned skins in the
lidocaine treatment group and the cyclosporin treatment group (OVA Cys) were significantly upregulated.
D, Compared with those of the OVA saline group, murine IFN-gmRNA expression level of the OVA Lido3.0
group was significantly upregulated while IL-4 and IL-17E mRNA expression levels of lidocaine treatment
groups (OVA Lido1.5 and OVA Lido3.0) and the cyclosporin treatment group (OVA Cys) were significantly
downregulated. No significant difference in IL-17A mRNA expression level was detected in any groups.
E, No significant difference was detected in the proportion of Treg cells in murine spleen and lymph nodes
in lidocaine treatment groups (OVA Lido1.5 and OVA Lido3.0) and the cyclosporin treatment group (OVA
Cys). *P < .05 and **P < .01. Bars indicate mean 6 SEM (n 5 5) of 2 independent experiments. Statistical
analyses were performed with nonparametric Mann-Whitney test.
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FIG E4. Effects of lidocaine on murine Treg-cell differentiation and its specific signaling pathway. A, The
safety level of lidocaine was verified as 0 to 0.8 mmol/L by CCK8 analysis. B, At the concentration of
0.8 mmol/L, the promotion of lidocaine to Treg-cell differentiation was not significantly relevant with nu-
clear factor kappa B signaling pathway (via Western blot). *P < .05, **P < .01, and ***P < .001. Bars indicate
mean 6 SEM of 3 independent experiments. Statistical analyses were performed with paired t test.
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